Close

BioXcel Therapeutics (BTAI) Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. CMG


Go back to BioXcel Therapeutics (BTAI) Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
(NASDAQ: BTAI) Delayed: 2.71 --0 (-0%)
Previous Close $2.71    52 Week High $ 
Open $2.71    52 Week Low $ 
Day High $2.71    P/E N/A 
Day Low $2.71    EPS $ 
Volume 750